Common
Bimagrumab
Chemical compound
Bimagrumab
Bimagrumab (BYM338) is a human monoclonal antibody first developed by Novartis and currently by Eli Lilly to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B. Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half-life and is administered once a month.
Open boosters, collect cards and trade them. Free to play.
Play for free